Clinical Trials
14 trialsNCT04035434 2025-10-24
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics
Phase 1/2 Terminated
NCT05296525 2025-03-25
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Gamida Cell ltd
Phase 1/2 Terminated
NCT05588440 2024-12-05
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Oncternal Therapeutics, Inc
Phase 1/2 Terminated
NCT05315713 2024-10-04
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1/2 Terminated
NCT05720052 2024-07-18
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MingSight Pharmaceuticals, Inc
Phase 1/2 Terminated
NCT05611853 2024-02-21
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
BioNova Pharmaceuticals (Shanghai) LTD.
Phase 1/2 Terminated
NCT02440685 2023-06-07
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
Phase 1/2 Terminated
NCT02898259 2022-09-26
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Case Comprehensive Cancer Center
Phase 1/2 Terminated
NCT02361346 2022-08-18
MT-3724NHL001
Molecular Templates, Inc.
Phase 1/2 Terminated
NCT02151903 2020-11-27
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
Alopexx Oncology, LLC
Phase 1/2 Terminated
NCT01874288 2020-11-24
DI-Leu16-IL2
Alopexx Oncology, LLC
Phase 1/2 Terminated
NCT02266147 2020-09-04
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Dynavax Technologies Corporation
Phase 1/2 Terminated
NCT02983097 2018-01-19
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 1/2 Terminated
NCT00768339 2011-07-13
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Aegera Therapeutics
Phase 1/2 Terminated